Adalimumab for the treatment of Behçet's disease: experience in 19 patients. - Wikidata - awgldk - TriplyDB

Adalimumab for the treatment of Behçet's disease: experience in 19 patients.

Adalimumab for the treatment of Behçet's disease: experience in 19 patients.

http://www.wikidata.org/entity/Q38020828

about

Biologics in dermatology: an integrated review Anti-TNF-alpha therapy and systemic vasculitis.Is Optimal Management of Recurrent Aphthous Stomatitis Possible? A Reality Check Biological treatments in Behçet's disease: beyond anti-TNF therapy.Autoimmune and autoinflammatory mechanisms in uveitis.Usefulness of Adalimumab for Treating a Case of Intestinal Behçet's Disease With Trisomy 8 Myelodysplastic Syndrome.Adalimumab effectiveness in Behçet's disease: short and long-term data from a multicenter retrospective observational study.Successful Discontinuation of Infliximab in a Refractory Case of Vasculo-Behçet Disease.Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis.Update on the Medical Management of Gastrointestinal Behçet's Disease.Update on the therapy of Behçet disease.Efficacy and safety of TNF-α inhibitors in refractory primary complex aphthosis: a patient series and overview of the literature.Current and future treatments for Behçet's uveitis: road to remission.Therapy of ocular Behçet disease.Behçet's syndrome pathophysiology and potential therapeutic targets.A comprehensive review and update on the biologic treatment of adult noninfectious uveitis: part II.Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?Certolizumab Pegol treatment in Behcet's disease with different organ involvement: A multicenter retrospective observational study.New therapeutic solutions for Behçet's syndrome.Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.Biologic Treatment Options for Retinal Neovascularization in Behçet's Disease.Autoimmune sensorineural hearing loss as presenting manifestation of paediatric Behçet disease responding to adalimumab: a case report.Anti-TNF therapy in the management of ocular attacks in an elderly patient with long-standing Behçet's disease.Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis.[Update: Behçet's disease].Long-term clinical outcomes in patients with refractory uveitis associated with Behçet disease treated with infliximab.Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network Anti-TNF- therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients Anakinra treatment in drug-resistant Behcet’s disease: a case series

P2860

Q27004638-5E703DFA-E8B6-4F87-B94A-95218ABAEFB4 Q27687590-F75E8723-83E7-45A1-9D42-FE3F995C2B59 Q28070375-7186716C-3A73-4EC7-8611-0F006A37B9DA Q33908217-37CA566D-E0E8-46DE-9385-D0C0F85459E5 Q34294964-57DB1BEA-FF3F-4751-91CD-1B715F57F80F Q35554192-BC843A43-2DE0-442F-AE54-BB0C6D659B4A Q36146582-F8C3A9FA-A99F-46E1-AB54-F153FC95BCB2 Q36731095-405E1457-8623-499C-AA36-3DFC1159ABB2 Q37105146-28E786E5-CD0B-4892-8D61-94084CD89FF9 Q37624811-EBB79148-5D75-400A-AFC4-B2A6EF3CFD67 Q37712230-F90169D9-D4A8-4610-99CD-3A9C05377D3A Q38101988-FF32BC56-C38B-48A3-B1DD-3514D8A92621 Q38111308-E755ED43-0793-4D7C-8EDE-49BAC43D639F Q38174652-3A601E68-AE90-4443-A03D-9A8A3DFE1001 Q38177749-3BC0487A-DE24-4D99-BF79-77A0A527D49B Q38250103-D6E28F6A-DCCE-4A7B-94FD-CD60D121C902 Q38631012-57FABCB5-C167-483C-982D-8635E65AEF2A Q38677010-9D6DF732-0BBB-40E9-8FBF-A4B33BBBE245 Q38830790-0D2B2CCE-FB0A-4BA7-99FD-895407305467 Q39181648-A41378EE-95D5-4061-9ECA-72394F5D55AA Q39430605-9065B9F3-6A2D-43EA-8E23-F1EE996425B2 Q40089935-58188FCC-7723-489C-9AE0-2CF60A257F68 Q41265511-CB8F6956-919C-4F40-83D8-76DE92EEFA27 Q48368367-F786FB3A-A53A-4728-A06C-61D8DC10CD90 Q48630386-C3AECDDE-9B45-4D96-AECF-FE04C8EBC472 Q50938469-350B5336-33CC-4864-8C88-871FE0B182A8 Q57612721-569184AD-B81A-455D-9BD1-D0729BFF9E08 Q57767895-05092C92-D95E-46D7-B3FE-BC0A9911FFB3 Q58326155-1BA62FE7-491B-4675-A3E1-E403A9AE7F04

P2860

Adalimumab for the treatment of Behçet's disease: experience in 19 patients.

http://www.wikidata.org/entity/Q38020828

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Adalimumab for the treatment of Behçet's disease: experience in 19 patients.

@en

type

label

Adalimumab for the treatment of Behçet's disease: experience in 19 patients.

@en

prefLabel

Adalimumab for the treatment of Behçet's disease: experience in 19 patients.

@en

P1433

Q38020828-B296DF17-237A-491E-AB27-14BC64637430

P1476

Q38020828-33578AF4-1CF6-4BE2-B525-C8D3D82AAA41

P2093

Q38020828-07017DB8-725D-4A10-99BC-778287D35E34

Q38020828-071CF1A2-6872-481A-BDD5-1DC77DA23970

Q38020828-C8D82B00-4FCD-4890-BE59-95DFBF84EA22

Q38020828-D6333452-598C-451C-A803-CC335AE58D12

Q38020828-DCCA929A-F5C3-493B-BF21-5D0711755E2C

P2860

Q38020828-028CCC5D-C9F0-4A2B-9A29-2A547D595DE0

Q38020828-294AA21C-9808-42D9-A5D5-87B2E5B4F996

Q38020828-40C461F0-35AD-416B-8DE4-D5F021A2B44D

Q38020828-49964E46-B5B8-43D4-B866-6305BC64F563

Q38020828-67504FCF-ADDA-46DB-A6EF-E52E9ED67C7B

Q38020828-6ECBAFCB-005E-4017-84DF-5191A3D8B41E

Q38020828-70199BF9-7ACA-433F-96E8-D28CFDBCA097

Q38020828-80599407-1920-4B92-AEC9-7C6DD0D64B62

Q38020828-85EE683E-C078-44FA-AB52-FD9091A38E48

Q38020828-8BC2E259-3A9E-4BB6-86FC-21BD759E0BB7

P304

Q38020828-CAC2BFEF-5B90-4593-A8A4-5458CA636810

P31

Q38020828-7295A4B1-A063-4C36-BC51-D524F7C0D0FC

P356

Q38020828-85C1E4B6-F94A-4B2A-AFF3-1DD3FF44D384

P433

Q38020828-DF96D70E-7E2C-49A0-80BA-4003AA8F20A6

P478

Q38020828-F65B4C29-4038-43DE-A8AA-00B465684240

P50

Q38020828-5C837B69-AC42-498C-8A97-F600E65B791F

Q38020828-6A2A2BF4-F297-4911-89DD-6471107D1D82

Q38020828-A2CBC270-B359-479A-8B2C-F2FBEC468997

Q38020828-A7458B32-4F0B-4B71-9E88-218422735B65

P577

Q38020828-2CF9E174-7760-4AF5-AB6C-0898DFD7E34E

P5875

Q38020828-99F0A4C2-99A8-4F5A-8589-11A57085A037

P698

Q38020828-4A5CED80-97C8-4593-95C5-B7F73B80C887

P921

Q38020828-73A4260E-734D-4977-9093-8CB14FD5448A

Q38020828-F94B607F-19B4-4762-BB44-311852EB4651

P356

P1433

P1476

Adalimumab for the treatment of Behçet's disease: experience in 19 patients.

@en

P2093

Daniela Perra

http://www.w3.org/2001/XMLSchema#string

José Luis Callejas

http://www.w3.org/2001/XMLSchema#string

Marco A Alba

http://www.w3.org/2001/XMLSchema#string

Norberto Ortego

http://www.w3.org/2001/XMLSchema#string

Raquel Ríos-Fernández

http://www.w3.org/2001/XMLSchema#string

P2860

Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis

Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop

Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody

EULAR recommendations for the management of Behçet disease.

Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease.

Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients.

Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study.

Behçet syndrome.

Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease.

The use of interferon alpha in Behçet disease: review of the literature.

P304

1825-1831

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/RHEUMATOLOGY/KES130

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P50

Marina Mesquida

Gerard Espinosa

P577

2012-06-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

227858033

http://www.w3.org/2001/XMLSchema#string

P698

22723596

http://www.w3.org/2001/XMLSchema#string

P921

Behcet's disease